Founded in 2014, Oxular is a retinal therapeutics company whose mission is to build a global ophthalmic franchise based on the successful development and commercialisation of our retinal treatments.
Our retinal treatments are engineered to access specific small spaces in the eye and to provide targeted drug distribution to tissues specifically involved in retinal diseases. Our unique approach aims to increase therapeutic effectiveness, increase duration of clinical effect, reduce drug side effects, reduce complications from administration procedures and minimise the frequency of dosing.
The annual global retinal therapeutics market is worth more than $9bn and is expected to double by 2023 as the world’s population ages, rates of chronic disease increase and populations get greater access to healthcare. Oxular is well placed to be a strong player in this market, offering innovative and quality-of-life-improving solutions.
Our product development pipeline includes treatments for both prevalent retinal diseases, such as age-related macular degeneration and diabetic macular oedema, as well as rare and orphan conditions.